Experience gained in the use of Coagyl-VII and evaluation of its hemostatic activity in a patient with inhibitory hemophilia A, receiving the drug in the home treatment setting after total knee arthroplasty

Recombinant activated factor VII (Coagyl-VII®, GENERIUM, Russia) was used in a patient with inhibitory hemophilia A after total knee arthroplasty. The patient injected Coagyl-VII on-demand at home in a dose of 60-120 μg/kg (median 90 μ/kg) -4.8-9.6 mg (median 7.2 mg) during one year. Use of the drug in this dose controlled all bleeding episodes and made it possible for the patient to activate the prosthesis and adapt to it properly. The efficacy and safety of therapy was evaluated by analysis of daily records of clotting factor injections, traditional coagulation tests, and thromboelastography.

ингибиторная гемофилия А, тотальное эндопротезирование коленного сустава, рекомбинантный активированный фактор VII, Коагил-VII, тромбоэластография, inhibitory hemophilia A, total knee arthroplasty, recombinant activated factor VII, Coagyl-VII, thromboelastography